Introduction: Expression of breast cancer metastasis suppressor 1 gene (BRMS1) is decreased in NSCLC cells and tumors. We hypothesized that intratumoral breast cancer metastasis suppressor 1 (BRMS1) expression is associated with lung adenocarcinoma (LUAD) histologic subtypes and overall survival (OS) and disease-free survival (DFS) in patients undergoing resection for early-stage LUAD.
Introduction
Risk factors to identify patients with surgically resectable lung adenocarcinoma (LUAD) who have a high risk for distant recurrence are poorly defined. 1 Currently, the most important prognostic factor for LUAD is TNM stage. 2 In addition to TNM stage, several clinicopathologic prognostic factors have been investigated, albeit in heterogeneous study populations. These include lymphovascular invasion, [3] [4] [5] visceral pleural invasion, 4, 5 and tumor size. 6, 7 Our group and others have identified specific LUAD histologic subtypes that are associated with poor prognosis. [8] [9] [10] This suggests that specific LUAD histologic subtypes have an underlying biology that is associated with an increased proclivity for development of metastases. More recently, genomic and immunologic profiling of LUAD has identified several genomic perturbations associated with poor prognosis, including mutations in KRAS gene, tumor protein p53 gene (TP53), and Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PI3K) and tumor programmed death ligand 1 immunoreactivity. [11] [12] [13] [14] Whereas considerable effort has been focused on understanding the mechanisms of metastases in advanced-stage lung cancer, little work has been done to identify biomarkers of metastases in early-stage, surgically resected LUAD.
Breast cancer metastasis suppressor 1 (BRMS1), which is expressed in all normal human tissues, maps to chromosome 11q13.1-13.2 and contains a helix-turnhelix DNA binding domain and coiled-coiled domains, which suggests that it may be part of a transcription complex. 15, 16 Breast cancer metastasis suppressor 1 gene (BRMS1) is one of more than 25 known metastasis suppressor genes that, together with their encoded proteins, inhibit metastasis formation in vivo without altering primary tumor formation. 17, 18 Previous studies have shown that BRMS1 mRNA and protein are decreased in NSCLC cells and patient tumor samples compared with in normal epithelial lung cells and adjacent noncancerous lung tissue. 16, 19 These observations suggest that lower intratumoral BRMS1 expression may be a putative biomarker of an increased risk for development of metastases.
We hypothesized that intratumoral BRMS1 expression is an independent prognostic marker of overall survival (OS) and disease-free survival (DFS) and that it contributes to a prediction model of increased metastatic potential in a large cohort of patients with surgically resected LUAD. To experimentally address this hypothesis, we used the Reporting Recommendations for Tumor Marker Prognostic Study guidelines 20, 21 and the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis prediction modeling criteria.
22,23

Materials and Methods
Patients
This study was approved by the institutional review board (WA0269-08) at Memorial Sloan Kettering Cancer Center. We reviewed 1030 patients who underwent an R0 surgical resection for LUAD at Memorial Sloan Kettering Cancer Center between 1995 and 2009 and had tumor blocks available for construction of tissue microarrays (see the CONSORT diagram in Supplementary   Fig. 1 ). Median follow-up was 5 years (range 0-14 years). Clinicopathologic data were collected from a prospectively maintained database. Disease stage was based on the seventh edition of the American Joint Committee on Cancer Staging Manual. 24 
Tissue Microarrays
As previously reported by our group, 25, 26 histologic subtyping of tumors was based on review of hematoxylin and eosin (HE)-stained slides from the surgical resection specimens. We then used the formalin-fixed, paraffinembedded tumor specimens to construct our tissue microarrays. In brief, four to nine representative tumor areas from the most predominant histologic pattern or the second most predominant pattern were marked on HE-stained slides, and cylindrical 0.6-mm tissue cores were arrayed from the corresponding paraffin blocks into a recipient block by an automated tissue arrayer (ATA-27 [Beecher Instruments, Sun Prairie, WI]).
Immunohistochemical Analysis and Scoring of BRMS1
In brief, 4-mm-thick sections from the microarray blocks were deparaffinized. Antigen retrieval was performed using citrate buffer (pH 6.0). The standard avidin-biotin-peroxidase complex was used for immunostaining of anti-BRMS1 antibody (EPR7202/ab134968 [Abcam, Cambridge, MA], diluted at 1:250). Sections were stained using a Ventana Discovery XT automated immunohistochemical stainer (Ventana Medical Systems, Tucson, AZ). Noncancerous adjacent lung tissues were stained as positive controls in parallel with the study tissues.
BRMS1 expression was initially evaluated using two components: distribution and intensity. Nuclear BRMS1 expression was diffusely expressed in at least 50% of the tumor area in each core distribution and was therefore not a good discriminator. Other groups have used distribution as a scoring criterion, and this may be related to antibody type, dilution, or tissue type undergoing immunohistochemical analysis-all of which were different in our study. Accordingly, BRMS1 expression was evaluated on the basis of intensity of nuclear immunostaining. BRMS1 nuclear staining was scored on the basis of intensity, with 0þ indicating no staining and 1þ , 2þ, and 3þ indicating weak, moderate, and staining, respectively. Staining of only the tumor cells was used when determining intensity of BRMS1 staining. One score per core was given. When a core exhibited heterogeneous tumor cell staining, the maximal score was used to give one score per core. For example, if 60% of the tumor cells showed moderate (2þ) nuclear staining and 40% showed strong staining (3þ), the core would be scored as 3þ. Cores lacking tumor cells were disregarded. Four to nine cores were used per patient; 395 patients had four cores each, 106 patients had five cores each, and 656 patients had nine cores each. The median number of tumor cores per patient available for analysis was five (25th-75th percentile, four to seven cores). The mean of all the patients' cores was used as the total score. Consistent with other BRMS1 immunostaining scoring, low BRMS1 expression was defined as an intensity score of 0 to 2 and high expression as a score of 3.
27,28 A pathologist blinded to patient outcomes and demographic characteristics independently analyzed the tissue microarrays. To determine concordance and agreement rates between pathologists, a second pathologist blinded to the analysis of the first pathologist examined 100 randomly selected patient samples (10% of the cohort, > 500 cores).
Histologic Subtype Evaluation
HE-stained tumor slides were reviewed by two pathologists who were blinded to clinical outcomes. Discrepancies in assignment of predominant histologic subtype between pathologists were resolved by consensus. Invasive adenocarcinomas were classified according to the 2015 WHO classification 29 and the 2011 IASLC/ATS/ERS classification. Invasive adenocarcinoma was subdivided into lepidic, acinar, papillary, micropapillary, and solid predominant subtypes. 30 Minimally invasive adenocarcinoma (n ¼ 29) was grouped with the lepidic histologic subtype. Tumors were also grouped by architectural grade, as low (lepidic predominant), intermediate (papillary or acinar predominant), or high (micropapillary or solid predominant). 8, 31 Nuclear features, lymphatic invasion, and vascular invasion were also assessed.
Statistical Analysis
Patient demographic and clinical characteristics were summarized using descriptive statistics. The association between clinicopathologic factors and BRMS1 expression (low versus high) was analyzed using Fisher's exact test for categorical variables and the Wilcoxon rank sum test for continuous variables.
The outcomes of interest were OS and DFS. Both OS and DFS were estimated by the Kaplan-Meier method: OS was defined from the time of surgery to the time of death from any cause, and DFS was measured from the time of surgery to the time of any recurrence or death from any cause. Patients were censored at the date of last follow-up. Associations between factors and survival were analyzed by using the log-rank test and univariable Cox proportional hazards regression model. Univariable analyses, including those with BRMS1 as the variable of interest, were stratified by pathologic stage. Key interactions between factors of interest were examined using Cox proportional hazards models for OS and DFS, including both main effects and the interaction term, and were reported as hazard ratios (HRs). The proportional hazards assumption for the Cox models of both outcomes was met on the basis of assessments of the scaled Schoenfeld residuals.
For multivariable models of OS and DFS, variable selection was guided by the all subset method using the Akaike information criterion, 32 including main and interaction terms with p < 0.1 from the univariable analyses. On the basis of published literature identifying factors associated with OS and DFS in this population, 1, [8] [9] [10] 33 some variables were chosen to remain in the multivariable models regardless of significance: IASLC predominant subtype, extent of resection (pneumonectomy, lobectomy, bilobectomy, and wedge), and pathologic stage. Continuous variables were tested for nonlinearity using restricted cubic splines, whereas categorical covariates were included as dummy variables.
Overall p values of categorical factors were calculated on the basis of Wald tests of linear hypotheses of the dummy variables.
The performance of the nomogram models was evaluated by discrimination (the Harrell C-index), 34 calibration (calibration plots), and overall accuracy integrated up to 5 years after surgery (integrated Brier score). 35 The C-index describes the proportion of pairs in which the responder has a higher predicted probability than the nonresponder; a C-index value closer to 1 implies that the nomogram has good discriminatory ability. Calibration plots visually compare the nomogrampredicted survival probabilities with the observed survival probabilities in groups with approximately equal sample sizes; the calibration curve would lie on the diagonal 45-degree line in an ideal nomogram. To overcome the issue of optimism from validating the multivariable models using the development cohort, we used bootstrapping to obtain bias-corrected (overfittingcorrected) estimates of the performance measures. We report results of the performance measures from both apparent performance (without bootstrap adjustments) and optimism-corrected performance (bootstrap corrected).
The OS and DFS nomograms were developed by using the multivariable Cox models, which allowed for calculations of survival probability estimates. The predictions of both OS and DFS nomograms were calculated for 5 years after surgery, as 5 years was the median follow-up time distribution for the cohort.
To assess the interrater reliability (IRR) of the scoring system, we used two chance-corrected agreement measures: Cohen's k and Gwet's AC1. Cohen's k is a conventional summary measure of the IRR given two raters. We also present the IRR measured by Gwet's AC1, which takes into account prevalence bias and potential "prevalence paradox," which occurs when one response is extremely common. 36 Both measures range from -1 to 1. Following the guidelines from Landis et al., a k statistic of 0.00 to 0.20 was considered to have slight agreement, 0.21 to 0.40 to have fair agreement, 0.41 to 0.60 to have moderate agreement, 0.61 to 0.80 to have substantial agreement, and 0.81 to 1.00 to have almost perfect agreement. 37 In addition, percent raw agreement was used to calculate the percentage of time that the raters agreed. Statistics were calculated with R 3.3.1 software (R Development Core Team, Vienna, Austria), using the IRR package and Gwet's user-written R functions. 27 All other statistical tests were two sided, and a p value less than 0.05 was considered statistically significant. Statistical analyses were performed using R 3.3.1 with the glmulti, pec, and rms packages (downloaded in January 2017) and Stata 13 (StataCorp LP, College Station, TX).
Results
Association between BRMS1 Expression and Clinicopathologic Factors
Representative photomicrographs of BRMS1 immunostaining are shown in Figure 1 . Analysis of BRMS1 expression for the entire cohort (n ¼ 1030) revealed
, and 3 (n ¼ 632 [61%]). Thus, 398 LUAD specimens (39%) had low BRMS1 expression, and 632 (61%) had high expression (see Fig. 1 ).
BRMS1 expression levels relative to specific clinicopathologic variables were then examined ( alternatively, only 25% of lepidic predominant tumors had low BRMS1 expression.
Relationship between BRMS1 Expression and OS
In the high-expression group, 209 (33%) patients died from any cause, with 423 (67%) alive at the end of the study. Comparatively, in the low-expression group, 215 patients (54%) died from any cause, with 183 (46%) alive at the end of the study. The 5-year OS rate was 75% (95% confidence interval [CI], 71%-78%) for the high-expression group and 66% (95% CI: 61%-71%) for the low-expression group. The corresponding median OS times were 10.7 (95% CI: 9.3-12.1) and 7.7 (95% CI: 6.7-9.5) years. A stratified log-rank test indicated significant difference in OS between the two groups (p ¼ 0.002 [ Fig. 2A]) . In univariable analysis, low BRMS1 expression was significantly associated with worse OS (HR ¼ 1.37, 95% CI: 1.12-1.67, p ¼ 0.002 [ Although it was not the primary objective of our study, to assess the relationship between BRMS1 mRNA expression and OS in early-stage LUAD, we examined two independent cohorts. Both the stage I LUAD Nagoya cohort (n ¼ 79) and the University of Michigan cohort (n ¼ 128) of LUAD patients without nodal metastasis had a robust decrease in OS with low BRMS1 mRNA transcript levels ( Supplementary Fig. 3 ). 28, 38 In a multivariable model that adjusted for age, sex, surgery type, pathologic stage, tumor size, lymphovascular invasion, and histologic subtype, the hazard of death for patients with low BRMS1 expression was 1.36-fold higher than that for patients with high expression (95% CI: 1.10-1.65, p ¼ 0.003 [see Table 2 ]).
The OS nomogram is used to predict the probability of death from any cause at 5 years ( Supplementary  Fig. 4 ). Calibration plots for internal validation of OS at 5 years are shown in Supplementary Figure 5 
Relationship between BRMS1 Expression and DFS
In the high-expression group, 249 patients (39%) died of disease or had locoregional or distant recurrence, with 383 (61%) alive without disease at the end of the study. Comparatively, in the low-expression group, 206 patients (52%) died of disease or had recurrence, with 192 (48%) alive without disease at the end of the study. The 5-year DFS rate was 65% (95% CI: 61%-69%) for the high-expression group and 57% (95% CI: 52%-62%) for the low-expression group. The corresponding median DFS times were 10.0 (95% CI: 7.9-11.4) and 6.6 (95% CI: 5.5-8.2) years. A stratified log-rank test indicated a significant difference in DFS between the two groups (p ¼ 0.0045 [ Fig. 2B]) . In univariable analysis, low BRMS1 expression was significantly associated with worse DFS (HR ¼ We then performed multivariable analysis that adjusted for age, sex, surgery type, pathologic stage, tumor size, lymphovascular invasion, and histologic subtype. Low intratumoral BRMS1 expression was an independent predictor of worse DFS compared with high BRMS1 expression (adjusted HR ¼ 1.25, 95% CI: 1.04-1.52, p ¼0.02 [see Table 3 ]).
The DFS nomogram is used to predict the probability of death from recurrent LUAD at 5 years (Fig. 3) . Calibration plots for internal validation of DFS at 5 years are shown (see Supplementary Fig. 5 ). The Harrell C-index for the DFS nomogram was 0.707 (95% CI: 0.682-0.730), with an internal validation C-index of 0.692 (95% CI: 0.667-0.720 [see Supplementary Table 1] ).
Discussion
We have shown that low intratumoral BRMS1 expression in surgically resected LUAD is associated with increased T stage, larger tumors, and more lymphatic and vascular invasion compared with high BRMS1 expression. Moreover, we found that BRMS1 expression is an independent predictor of OS and DFS in our patient cohort. Patients with surgically resected LUAD and low intratumoral BRMS1 expression had worse OS and DFS than patients with high BRMS1 expression. Specifically, the hazard of death and hazard of disease recurrence or death among patients with low BRMS1 expression were 1.36-and 1.25-fold, respectively, compared with those among patients with high BRMS1 expression after adjustment for relevant factors. Collectively, these findings show that BRMS1 expression has prognostic and functional significance in surgically resected LUAD. Selected metastasis suppressor genes have been implicated in the metastatic cascade associated with NSCLC. Decreased levels of CD82 molecule gene (KAI1) and KISS-1 metastasis-suppressor gene (KISS1) have been associated with worse prognosis in a small series of mixed histologic types, treatment strategies, and variable stages. 39, 40 In contrast, the roles that other well known metastasis suppressor genes, such as NME/NM23 Nucleoside Diphosphate Kinase 1 (NM23), mitogen-activated protein kinase kinase 4 gene (MKK4), and Rho GDP Dissociation Inhibitor Beta, play in the biology of lung cancer metastases are less well characterized. [41] [42] [43] [44] We first reported that BRMS1 expression was reduced in NSCLC cells and human tumor tissues and was associated with worse OS, suggesting possible prognostic relevance. 45 In that small (n ¼ 80) exploratory study of mixed NSCLC histologic types and stages, BRMS1 expression did not correlate with histologic grade or lymphatic invasion. However, in this larger study of surgically resected LUAD only, lymphatic invasion and tumor size correlated with intratumoral BRMS1 expression.
This study extends observations from other groups on the prognostic relevance of BRMS1 expression for solid tumors. Low BRMS1 expression, as measured by immunohistochemical analysis, has been identified as an independent predictive factor for poor prognosis in nasopharyngeal carcinoma, 46 gallbladder adenocarcinoma, 47 and melanoma. 48 Collectively, this and other studies illustrate more broadly the consequences of BRMS1 loss for cancer progression and its impact on survival in patients with solid tumors of different histologic profiles and organ types.
Loss of BRMS1 expression in NSCLC and other solid tumors occurs at the chromatin level, where promoter methylation results in transcriptional repression. 45, 49 Specifically, we have demonstrated that RelA/p65-DNA methyltransferase 1-mediated BRMS1 promoter methylation results in transcriptional repression of BRMS1 in lung cancer. 49 Methylation of the BRMS1 promoter has also been shown to correlate with smoking history and poor survival. 45, 50 Although it was not the primary objective of this study, we found that decreased BRMS1 transcript levels were associated with decreased OS in two independent study cohorts of early-stage, node-negative LUAD. In addition, we recently showed that BRMS1 expression is posttranslationally regulated through phosphorylation on serine 30 by CK2a 0 . This results in 14-3-3-mediated nuclear exportation of BRMS1 and its subsequent proteasome-mediated ubiquitination and degradation. 51 Both of these mechanisms have potential clinical implications, as serum cfDNA BRMS1 promoter methylation has been shown to be an Figure 3 . The disease-free survival (DFS) nomogram provides a graphic approach to calculate 5-year DFS after resection on the basis of a patient's combination of clinicopathologic covariates. First, locate the patient's age and draw a line straight up to the points axis to derive the score associated with an age. Repeat for the other covariates on the nomogram. Add the scores for each covariate to determine the total score. Draw a vertical line from the total points axis to the 5-year DFS axis to obtain the predicted probability. PN, pneumonectomy; Seg, segment; BRMS1, breast cancer metastasis suppressor 1; OS, overall survival; LPD, lepidic; ACI, acinar; PAP, papillary; SOL, solid; MIP, micropapillary.
independent predictor of OS and DFS in early-stage NSCLC 52 and small-molecule inhibition of CK2a 0 with CX4945, a drug currently in clinical trials, resulted in a 60-fold reduction of extrathoracic metastases in our orthotopic lung cancer model. 51 Collectively, these observations suggest that with appropriate validation, intratumoral BRMS1 expression may be pharmacologically modified; this is a testable hypothesis for future clinical trials.
The strengths of this study include the large number of patients (N ¼ 1030) , the focus on a single tumor histologic subtype (LUAD), and the use of a homogeneous patient cohort. A further strength is the reproducibility of the scoring system: the raw observed agreement of the tested 100 cases was 96%, and only four cases were discordant. Cohen's k indicates that the IRR was substantial (0.84 [95% CI: 0.68-0.99]), and Gwet's AC1 indicates that the IRR was excellent (0.95 [95% CI: 0.90-1.00]). Additional strengths include the completeness of the clinical and pathologic annotation and the long follow-up, the internal validation of the data, and the development of nomograms to predict OS and DFS using strict Reporting Recommendations for Tumor Marker Prognostic Study and Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis criteria. To our knowledge, this is the first study to examine BRMS1 expression as a prognostic biomarker in surgically resected lung cancer independent of other well-described clinicopathologic variables. Finally, we make a hypothesis-generating observation that loss of intratumoral BRMS1 expression is associated with intermediate and high histologic architectural tumor grades in LUAD. This suggests that previously described epigenetic, posttranslational, and other unknown mechanisms governing BRMS1 expression may be particularly relevant in specific LUAD histologic subtypes.
Limitations of this study include the examination of an isolated biomarker by the use of immunohistochemical analysis. However, an integrated approach that combines gene and/or protein expression with associated clinicopathologic information may be best for biomarker classification and discovery. 38 A second limitation is the lack of inclusion of other tumor genomic mutations or translocations in our multivariable models. This was intentional, as we wanted to specifically examine the role of BRMS1, a metastasis suppressor gene, and not oncogenes, tumor suppressor genes, or oncogenic kinases. Moreover, it has become evident that discrete metastatic processes can be regulated independently of oncogene-driven tumor growth. 17 A third limitation is that the contribution of BRMS1 to the predictive abilities of the nomogram is small. This is likely secondary to the a priori selection of clinicopathologic criteria that result in a very robust model without BRMS1 and a focus on early-stage LUAD-and not on node-positive, advanced-stage disease, for which the contribution of BRMS1 may be greater. Finally, a fourth limitation is the need for external validation of findings on the relevance of BRMS1 as a prognostic biomarker in LUAD.
In conclusion, loss of intratumoral BRMS1 expression is an independent predictor of decreased DFS and OS in a large cohort of patients with surgically resected LUAD. Targeting metastases is an increasingly attractive option to prevent initial metastases in high-risk patients, to shrink established lesions, and to prevent additional metastases in patients with limited disease. 53 This study opens the door to future clinical trials enriched for specific high-grade LUAD histologic subtypes that will test therapies and their ability to increase BRMS1 expression, decrease metastases, and improve DFS.
